Utility of Alzheimer's Blood-Based Biomarkers in the General Population

Michelle M. Mielke, PhD
Chair, Department of Epidemiology and Prevention
Wake Forest University School of Medicine

Learning Objectives

• Describe the use of Alzheimer's blood-based biomarkers in a large US health system.
• Explain how Alzheimer's blood-based biomarkers can be best utilized in a primary care clinical pathway.

Disclosures

• Planners: Bruce L. Miller, MD, Howard J. Rosen, MD, and Anil Vora have stated that they have no relationships with ineligible companies to disclose.
• Speaker: Michelle M. Mielke, PhD, has stated that she has no relationships with ineligible companies to disclose.

Accreditation: In support of improving patient care, this activity has been planned and implemented by UCSF Office of CME and the Edward and Pearl Fein Memory and Aging Center. UCSF Office of CME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 
‌
‌This CME activity meets the requirements under California Assembly Bill 1195 for continuing education and cultural and linguistic competency.

Designation: UCSF designates this live activity for a maximum of 22 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Credit is inclusive of all Edward and Pearl Fein Memory and Aging Center Grand Rounds sessions offered from January 1, 2026, through December 31, 2026. (1 credit per each 1-hour grand rounds session throughout the year).

Attendees must register to attend this event virtually. Grand Rounds presentations are for educational purposes and intended for a professional audience with a terminal degree. This activity is not commercially supported.